HomeTagsOBI Pharma USA Inc

Tag: OBI Pharma USA Inc

spot_imgspot_img
Medical

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual...

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and...
Medical

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine OBI Pharma (4174.TWO) announced that it has entered into a commercial...
Medical

OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. OBI...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img